Business Wire

FL-APPLIED-DATA-CORP

5.10.2021 16:03:10 CEST | Business Wire | Press release

Share
ADC Acquires Pinpoint Software, Continues to Expand Total Store Operations Platform

Applied Data Corporation (ADC), the global market leader for its SaaS-based total store operations platform built for retailers , today announced that it has entered into an agreement to acquire Pinpoint Software, Inc., a provider of software solutions driving operational efficiencies and execution for grocers and other retailers, including the world’s leading expiration date management platform, Date Check Pro® . The acquisition is a highly strategic addition to the ADC portfolio which includes ADC’s fresh item management platform, FreshIQ® , and fulfillment orchestration platform, ShopperKit, and will result in a solution that not only reduces food waste and delivers higher sales, but ultimately goes beyond sustainability to a more regenerative approach for retailers.

For most in the global retail space, food waste is a top concern that impacts the bottom line. As wasted food is the number one item going into landfills and contributing to GHG emissions, it is in everyone’s best interest to tackle this issue head-on. Both ADC and Pinpoint share a combined vision to arm retailers with the tools needed to drive sustainability results through a combination of quantification, analysis, and action.

“ADC’s trajectory as a total store operations platform continues to expand to meet the needs of retailers in today’s evolving market,” said Shamus Hines, CEO of ADC. “Pinpoint helps retailers proactively track inventory expiration dates across the store and work together with shoppers to minimize food waste.” Hines adds further, “As a company, we’re committed to enhancing all store operations for food retailers. With elevated consumer interest in sustainability, retailers are faced with the challenge to reduce food waste while also driving sales, and that is where both ADC and Pinpoint come into play.”

For nearly three decades, ADC has been a trusted provider to over 20,000 grocery and convenience store locations. The company’s SaaS platform of industry-tailored retail solutions already includes fulfillment orchestration, recipe management, made to order, label printing, inventory and waste management, food traceability, production planning, ordering, and temperature monitoring. With the addition of Pinpoint’s Date Check Pro , ADC will be able to offer additional reductions in shrink from expired products while also increasing customer satisfaction.

Andrew Hoeft, Founder and CEO of Pinpoint states, “At Pinpoint, we’ve always believed in driving efficiency and ensuring the freshest shopping experience possible for customers. ADC started in Fresh and has a strong belief in helping retailers reduce waste. Combined with our shared emphasis on user adoption with solutions that are easy to use and learn, joining forces with ADC was a perfect marriage. By blending our teams’ knowledge and solutions, we will continue to push the limits of retail operations technology.”

With this acquisition, work will immediately begin on an integration between the platforms in the coming weeks, the ADC website will be enhanced to show the full scope of the combined company.

About Applied Data Corporation

For more than 30 years, ADC has been a food technology innovator. Our platforms, FreshIQ® and ShopperKit, offer retailers an omnichannel approach to total store operations. FreshIQ allows retailers to effectively plan, prepare, analyze, and deliver the fresh food items shoppers want. The ShopperKit platform enables in-store order fulfillment for retailers to receive, prioritize, and process orders from their online counterparts allowing grocers to offer in-store pickup or delivery services to their online customers. ADC’s products are deployed globally in more than 120 grocery and convenience store chains and more than 20,000 locations. Visit www.applieddatacorp.com to learn more.

About Pinpoint

Pinpoint Software, Inc. is the parent company behind Date Check Pro. Founded in 2011 and based in the rapidly growing tech community and grocery tech hub of Madison, WI, Date Check Pro got its start when its founder Andrew Hoeft set out to solve the problem of expired shrink. Today, we help over a thousand supermarket, retail, and convenience store locations around the world eliminate their losses from dated and expired products and provide better products and experiences for their shoppers.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye